GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

For patients with Gleevec (imatinib)-resistant or intolerant gastrointestinal stromal tumors (GIST), treatment with ...

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

(mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; ...

Cogent Biosciences (NASDAQ: COGT) shares skyrocketed over 120% after the biotech company announced groundbreaking results ...

We recently published 10 Market Movers That Made Millionaires in a Week. Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the ...

Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...

Gastrointestinal stroma tumors (GIST) are cancers that start in specialized nerve cells found in the digestive system, from the esophagus and stomach to the intestines and rectum. They are rare, but ...

Long-term survival (over 10 years) of inoperable/metastatic GISTs: A retrospective series of 141 patients (pts) of the french sarcoma group (FSG). This is an ASCO Meeting Abstract from the 2017 ASCO ...

GIST stands for gastrointestinal stromal tumor. When tumors spread from the gastrointestinal (GI) tract to distant tissues or organs, it is called a metastatic GIST. Newer therapies, such as imatinib ...